ERBB2 and metastatic neoplasm: One resistance mechanism seems to be selective elimination of HER2-overexpressing clones, which leaves residual HER2-negative metastatic disease.31,32 In patients with HER2-positive metastatic disease treated with trastuzumab-based chemotherapy, 35% showed loss of HER2 amplification in post-therapy tissue biopsy specimens.31